Core Insights - Creative Medical Technology Holdings, Inc. announced promising one-year follow-up data from the AlloStem (CELZ-201) pilot study for late-stage Type 2 Diabetes, demonstrating significant efficacy and safety [1][2][3] Study Results - CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported [2][3] - The study involved 20 patients, with 10 receiving CELZ-201 and 10 undergoing optimized medical therapy, validating the safety and efficacy of CELZ-201 [3] Future Development Plans - The company plans to advance the development of AlloStem (CELZ-201) for late-stage Type 2 Diabetes and explore other potential applications to expand its pipeline [4] - The positive data represents a significant milestone in the company's mission to revolutionize diabetes treatment [5] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on developing regenerative cell therapies targeting various conditions, including endocrinology and immunotherapy [7]
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program